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Abstract: In the endometrium transforming growth factor-betas (TGF-βs) are involved mainly in menstruation and en-
dometriosis. After binding of the ligands to the high-affinity receptors, TGF-β receptors (TBR1 and TBR2), TGF-βs acti-
vate Smad signaling to modulate gene expression and cellular functions. However, recently also Smad-independent 
pathways have been studied in more details. To evaluate both pathways, we have analyzed TGF-β signaling in human 
endometrial and endometriotic cells. Although endometrial and endometriotic cells secrete TGF-β1, secretion by 
stromal cells was higher compared to epithelial cells. In contrast, secretion of TGF-β2 was higher in endometriotic 
stromal and endometriotic epithelial cells compared to normal endometrial cells. Treatment of endometrial and en-
dometriotic stromal and epithelial cells with TGF-β1 or TGF-β2 increased Smad-dependent secretion of plasminogen 
activator inhibitor-1 (PAI-1) dramatically in all three cell lines. Of note, endometriotic cells secreted clearly higher 
levels of PAI-1 compared to endometrial cells. Whereas a TBR1 kinase inhibitor completely blocked the TGF-β1 or 
TGF-β2-induced PAI-1 secretion, an ERK1/2 inhibitor only partially reduced PAI-1 secretion. This inhibition was not 
dependent on epidermal growth factor receptor (EGFR) activation by phosphorylation but on kinase activity of the 
TBR1. Finally, treatment of endometrial and endometriotic cell lines with recombinant PAI-1 showed reduced cell 
adhesion, especially of the endometrial cells. In summary, our results demonstrate that both Smad-dependent and 
TBR1-dependent ERK1/2 pathways are necessary for TGF-β-dependent high level secretion of PAI-1, which might 
increase cellular deadhesion.
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Introduction
TGF-βs are one of the most essential growth 
factors involved in cell differentiation, prolifera-
tion, motility, cancer and apoptosis in various 
cell types [1]. The Smad-dependent pathway is 
the main pathway of TGF-β signaling and is acti-
vated by phosphorylation of TBR1 which in turn 
phosphorylates Smad2/3 [2]. Additionally also 
Smad-independent pathways modulate signal 
transduction of TGF-βs (e.g. [3, 4]). 
In the human endometrium TGF-βs are differ-
entially and stage-specifically expressed [5]. 
The highest expression of TGF-βs was detected 
during menses [6] and TGF-β1 is also elevated 
in serum and peritoneal fluid of women with 
endometriosis [7, 8]. Furthermore, TGF-β1 is 
also differentially expressed in ovarian endo-
metriosis and might play a role as an activator 
[9].
Endometriosis affects 10% of the female popu-
lation in their reproductive ages [10] and is 
characterized by endometrial-like tissue grow-
ing outside the uterine cavity, mostly in the 
ovary and the peritoneum [11]. Besides animal 
models to study endometriosis (e.g. [12]), endo-
metriotic cell lines with characteristics compa-
rable to primary endometriotic cells have been 
established [13, 14]. Of note, these cell lines 
offer the possibility to study epithelial cells, 
which are otherwise rarely analyzed in the 
research of endometriosis in vitro.  
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In endometrial cells, TGF-βs showed different 
effects on cell proliferation. TGF-β1 stimulated 
proliferation of low epithelial cell numbers, but 
inhibited it at high cell numbers in women with 
and without endometriosis [15]. However, all 
three TGF-β isoforms inhibited proliferation of 
endometrial stromal cells in vitro [16].
In a nude mouse model, preincubation of endo-
metrial tissue with TGF-β1 together with pro-
gesterone before xenografting suppressed 
endometriosis-like lesion formation [17]. Po- 
ssibly, TGF-β1 restored the ability of progester-
one to suppress matrix metalloproteinases 
(MMPs) and thus prevented the establishment 
of endometriosis. However, TGF-β1 knockout 
mice on a background of SCID showed reduced 
lesion development of xenotransplanted hu- 
man endometriotic tissue [18].
Remarkably, TGF-βs, especially TBR1, are also 
involved in myometrial development [19, 20]. 
Furthermore, TGF-βs induced contraction of 
endometrial stromal cells in vitro [16], which 
might contribute to abnormal myometrial con-
tractions found in women with endometriosis 
[21, 22] probably resulting in increased dis-
semination of endometrial fragments.
In this study we aimed to investigate the TGF-β 
signaling pathways in endometrial and endo-
metriotic cells to identify possible targets which 
might be involved in the pathology of endo- 
metriosis.
Materials and methods
Cell lines
The stromal T-HESC cells ([23] ATCC CRL-4003) 
have been isolated from normal endometrium 
and demonstrate typical endometrial charac-
teristics [24]. The stromal cells 22B and epithe-
lial cells 12Z have been isolated from active 
peritoneal endometriotic lesions ([14] gener-
ously provided by Dr. Starzinski-Powitz, Frank- 
furt, Germany). The cell lines show characteris-
tics of the active phase of endometriosis and 
thus are suitable for studying cellular and 
molecular behaviour of endometriosis [24].
Cell culture
3x105 cells were seeded into 6-well plates (TPP, 
Switzerland) in DMEM high glucose or DMEM/
F12 media (+ 10% FCS). After culturing over-
night (37°C, 5% CO2), cells were starved in 
fresh medium (+ 1% FCS) for 6 hours. After 
removal of the old medium, fresh medium con-
taining 10 ng/ml recombinant human (rh)-
TGF-β1 or rh-TGF-β2 (Promokine, Germany), 
respectively was added. In the untreated con-
trols only 1x PBS was added to the medium. 
Cells were cultured (37°C, 5% CO2) for up to 
three days.
To investigate the pathways that might be 
involved in TGF-β signaling with respect to PAI-1 
secretion, several inhibitors targeting different 
pathways were used: the TGF-β receptor type I 
kinase inhibitor: 5 µM LY364947 (Sigma-
Aldrich, USA [25]) and 5 µM of the ERK inhibitor 
II (Merck, Germany [26]) dissolved in DMSO. 
The optimal dose was determined in prerun 
experiments. Inhibitors for other pathways like 
p38 MAPK (SB203580), PI3K (LY 294002), 
pKA (H-89) or JNK (JNK inhibitor II) were less 
effective on PAI-1 secretion.
Fresh media (+ 1% FCS) in 6-well with or with-
out inhibitor(s) was added. The untreated con-
trols were done with DMSO as vehicle. After an 
incubation of 2 hours (37°C, 5% CO2), cells 
were stimulated with 10 ng/ml TGF-β1 or TGF-
β2 as described above.
Supernatants were collected and mixed with a 
Protease Inhibitor cocktail (Sigma-Aldrich, 
USA). After centrifugation (5000x g, 10 min, 
4°C) the supernatants were aliquoted and 
stored at -20°C until use in the ELISAs. Then 
cell numbers were determined as described 
below. 
Cell numbers
After removal of the medium, cells were washed 
two times with 1x Dulbecco’s PBS with Ca2+ and 
Mg2+. Then accutase was added at 37°C until 
all cells were detached. After adding fresh 
medium, 10 μl of the cell suspension was trans-
ferred to a CASY tube with 10 ml CASY ton solu-
tion and mixed thoroughly. Then the cell num-
bers and cell viability were measured with a 
CASY-counter (Schaerfe System, Germany). 
Cell adhesion assay
1×106 cells/ml were seeded in 6-well plates 
and treated with active recombinant human-
PAI-1 (final concentrations of 40 nM, 20 nM, 10 
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nM or 5 nM). The buffer (50 mM NaH2PO4, 150 
mM NaCl, 1 mM EDTA, pH 6.6) used to dissolve 
PAI-1 was used for the untreated control. After 
4 hours (37°C, 5% CO2) the cell numbers were 
quantitated with the CASY Counter.
endometrial cells (Figure 1B). All cell lines only 
secreted very low levels of TGF-β3 (data not 
shown). In the next step, we investigated secre-
tion of the TGF-β-regulated protein PAI-1. In 
contrast to the epithelial cell line 12Z the stro-
Figure 1. Quantification of TGF-β1, TGF-β2 and PAI-1 secretion by all cell 
lines. Stromal cell lines T-HESC and 22B secreted higher levels of TGF-β1 
compared to epithelial cells 12Z (A). Endometriotic cell lines 22B and 
12Z secreted more TGF-β2 compared to endometrial cells T-HESC (B). 
Endometriotic stromal cells 22B secreted 4-fold higher levels compared 
to endometrial stromal cells T-HESC. Endometriotic epithelial cells 12Z 
secreted modest amounts of PAI-1 (C). Each experiment was repeated 
three times in duplicates (A+B); each experiment was repeated nine 
times in duplicates (C).
ELISAs
Quantitation of protein secretion 
was performed with the following 
ELISAs: PAI-1 Antigen ELISA Kit 
(Technoclone), and TGF-β1 and 
TGF-β2 DuoSets (both from R&D 
Systems). Latent TGF-β isoforms 
were activated with HCl followed 
by neutralization with NaOH as 
indicated by the supplier. Each 
ELISA was performed according 
to the manufacturer’s instruc-
tions and quantitated with the 
Benchmark Reader infinite M20- 
00 (Tecan). Cell numbers were 
used for standardization.  
Statistical analysis
Each experiment was repeated 
independently at least three 
times in duplicate. Values from all 
experiments were used to calcu-
late the means and the respec-
tive errors of the mean (SEM). 
Comparison between groups was 
done with the ANOVA followed by 
the post-hoc tests of Tukey and 
Dunnett by using GraphPad Instat 
3 (GraphPad). p values less than 
0.05 were considered statistical-
ly significant.
Results
To study endometrial and endo-
metriotic cells in vitro, three cell 
lines from the human eutopic and 
ectopic endometrium were used. 
All cell lines secreted TGF-β1 
(Figure 1A) as well as TGF-β2 
(Figure 1B). The stromal cell lines 
(T-HESC and 22B) secreted high-
er levels compared to the epithe-
lial cell line 12Z (Figure 1A). 
Interestingly, the endometriotic 
cell lines 22B and 12Z secreted 
more TGF-β2 than the normal 
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mal cell lines produced high amounts of PAI-1 
(Figure 1C). The endometriotic stromal cells 
22B secreted approx. 4-fold higher levels com-
pared to the endometrial stromal T-HESC. In 
contrast the endometriotic epithelial 12Z cells 
secreted only modest amounts of PAI-1. Taken 
together, PAI-1 secretion of the stromal cells is 
studied. However, we found that the EGF recep-
tor is not phosphorylated by the TGF-βs (data 
not shown).
Besides effects of PAI-1 on activation of plas-
min, it was also reported that PAI-1 inhibited 
cell attachment to the extracellular matrix (ECM 
much higher compared to the 
epithelial cells, whereas endo-
metriotic cells secrete higher 
amounts of TGF-βs than the 
normal endometrial cells. 
In order to elucidate the signal-
ing pathways involved in se- 
cretion of PAI-1, we analyzed 
Smad-dependent and Smad-
independent pathways with 
pharmacological inhibitors. Our 
results showed that both TGF-
β1 and TGF-β2 strongly incre- 
ased secretion of PAI-1 in all 
cell lines studied (Figure 2). 
The inhibitor LY364947 was 
described to inhibit phosphory-
lation of Smad2 and Smad3 by 
blocking the kinase activity of 
TBR1 [27]. Addition of LY36- 
4947 to the cells together with 
TGF-β1 or TGF-β2 strongly 
decreased PAI-1 secretion to 
levels comparable to the un- 
treated controls (Figure 2), 
demonstrating that mainly the 
Smad pathway is responsible 
for TGF-β-induced PAI-1 secre-
tion in endometrial cells.
Analysis of several Smad-in- 
dependent pathway inhibitors 
as indicated in the Materials 
and Methods section revealed 
only for the ERK pathway a sig-
nificant contribution to secre-
tion of PAI-1 (Figure 3). Our 
results showed that the TGF-
β1-induced or TGF-β2-induced 
PAI-1 secretion was reduced by 
a highly selective ERK1/2 
inhibitor by 35-50% in the cell 
lines studied. Furthermore, our 
results showed that stimulation 
with TGF-β1 or TGF-β2 strongly 
enhanced phosphorylation of 
ERK1/2 in all three cell types 
Figure 2. Treatment of cells with TGF-β1 or TGF-β2 (10 ng/ml), respectively, 
induced PAI-1 secretion in endometrial stromal T-HESC cells (A), endome-
triotic stromal 22B cells (B) and endometriotic epithelial 12Z cells (C). The 
TBR1 inhibitor (LY364947) blocked TGF-β-induced PAI-1 secretion of all 
cell lines studied completely to control levels (***P<0.001; **P<0.01; 
*P≤0.05). Each experiment was repeated three times in duplicates. Ctrl, 
control; TBRi; TBR1 inhibitor; B1, TGF-β1; B2, TGF-β2.
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[28]). In order to test this hypothesis, cells were 
stimulated with or without recombinant PAI-1 
for four hours and then the cell numbers were 
counted. PAI-1 decreased the number of adher-
ent cells in a dose-dependent manner (Figure 
4). Interestingly PAI-1 demonstrated stronger 
inhibitory effects on the endometrial cell line 
to women without endometriosis. Also PAI-1 
levels were higher in ectopic tissues than in 
eutopic tissues of the same woman [33].
Although there are many genes targeted by 
TGF-βs, PAI-1 is one of the most highly upregu-
lated [34]. Accordingly we found a Smad-
Figure 3. TGF-β1 or TGF-β2 induced PAI-1 secretion was moderately but 
significantly inhibited by the ERK inhibitor (ERKi) in endometrial stromal 
T-HESC cells (A), endometriotic stromal 22B cells (B), and endometriotic 
epithelial 12Z cells (C) by 50%, 30%, and 40%, respectively (**P<0.001, 
**P<0.01; *P<0.05). Each experiment was repeated three times in dupli-
cates. Ctrl, control; B1, TGF-β1; B2, TGF-β2.
T-HESC compared to the endo-
metriotic cell lines 22B and 
12Z. In addition to cell num-
bers, the CASY counter also 
measures cell vitality, which 
however was similar in all cell 
lines studies. Thus, we could 
exclude reduced cell adhesion 
by cell death.
Discussion 
In our study, we quantified 
secretion of TGF-β1 and TGF-
β2 by endometrial and endo-
metriotic cell lines and demon-
strated that TGF-β1 secretion 
was higher in stromal cells in 
comparison to the epithelial 
cells. Of note, endometriotic 
cell lines secreted considerably 
higher levels of TGF-β2 com-
pared to normal endometrial 
cell lines. Our results concur 
with those of Pizzo et al. [7] 
who reported increased TGF-
β2 secretion by endometrial 
cells at advanced stages of 
endometriosis. Similarily, Che- 
gini et al. [29] observed in- 
creased TGF-β2 secretion in 
surgically induced endometri- 
osis. 
Besides the main function of 
PAI-1 to inhibit the tissue/uroki-
nase plasminogen activator 
(tPA/uPA) induced fibrinolysis, 
PAI-1 is important also in adhe-
sion, migration, signal trans-
duction and anti-apoptosis [30, 
31]. In endometrial and endo-
metriotic tissues, Bruse et al. 
[32, 33] showed that expres-
sion of PAI-1 and uPA is much 
higher in endometriotic and 
endometrial tissue of women 
with endometriosis, compared 
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dependent increased secretion of PAI-1 in 
endometrial and endometriotic cells upon stim-
ulation with TGF-β1 or TGF-β2 in vitro. Our 
results showed clearly that endometriotic cells 
secreted more PAI-1 than the endometrial cells, 
and stromal cells (endometrial and endometri-
otic) secreted considerably more PAI-1 com-
pared to epithelial cells. Our results concur with 
those of Bruse et al. [33] who showed that PAI-1 
is mainly produced by endometrial endothelial 
and stromal cells.
endometrial and endometriotic cells (data not 
shown). 
Czekay et al. [39] showed that PAI-1 lowered 
attachment of cells to the ECM through inhibi-
tion of uPAR-vitronectin interaction, suggesting 
that PAI-1 negatively affects the cell-to-ECM 
connection. We found that recombinant PAI-1 
reduced cell attachment in all cell lines studied. 
This effect is not due to increased apoptosis, 
because PAI-1 is nearly exclusively described 
Figure 4. PAI-1 dose dependently inhibited cell adhesion of endometrial 
stromal T-HESC cells (A), endometriotic stromal 22B cells (B), and endome-
triotic epithelial 12Z cells (C). The numbers of attached cells decreased in 
a range of 2-40% after treatment for four hours with various concentrations 
of recombinant PAI-1 (***P<0.001, **P<0.01, *P<0.05). Each experiment 
was repeated three times in triplicates.
To investigate possible Smad-
independent pathways, we 
used several inhibitors, but 
found only for ERK a moderate 
but significant downregulation 
in TGF-β1- and TGF-β2-induced 
secretion of PAI-1 in all cell 
lines. Thus, besides Smad sig-
naling, the ERK pathway con-
tributes to high level secretion 
of PAI-1 in endometrial and 
endometriotic cells. Interes- 
tingly, there are several con-
nections between the TGF-β-
induced Smad pathway and 
the ERK pathway [35], for 
example the small GTPase 
Ras and the ERKs are impli-
cated in TGF-β signaling [3]. 
Similarly, TGF-β phosphorylat-
ed ERK Ras-dependently and 
through activation of p21 acti-
vated kinase-2 [36]. Furth- 
ermore activated TBR1 direct-
ly phosphorylated ShcA (Src 
homology 2 domain contain-
ing) inducing association with 
GRB2 (EGF receptor-bound 
protein-2) and SOS (son of 
sevenless), which then leads 
to a sequential activation of 
Ras, Raf, MEK1/2 and ERK- 
1/2 [37]. These data suggest 
that ERKs can be activated 
directly by the TBR1 without 
involvement of the Smad path-
way or EGF receptor phos-
phorylation, the latter is nor-
mally required for phospho- 
rylation of ERKs [38]. In this 
study, we did not observe 
phosphorylation of EGF recep-
tors after TGF-β stimulation of 
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as an anti-apoptotic protein [31]. Of note, in our 
study PAI-1 demonstrated stronger inhibitory 
effects on endometrial compared to endometri-
otic cells. Thus, we suggest that PAI-1 might 
play a role in endometriosis by facilitating 
detachment of endometrial cells. 
In conclusion, we showed in this study that 
mainly stromal cells secrete TGF-βs and PAI-1, 
which in the case of PAI-1 is regulated Smad-
dependently and Smad-independently by ERKs. 
However, we could also show that epithelial 
cells contribute to secretion of TGF-βs and 
PAI-1 albeit only moderately. The connection of 
the ERK pathway to TGF-β signaling as suggest-
ed in this study seems to depend only on the 
kinase activity of the TBR1. Moreover, it is strik-
ing that we found no apparent differences in 
cell signaling between endometrial and endo-
metriotic cells. However, we hypothesize that 
increased TGF-β and PAI-1 levels as observed 
in women with endometriosis might possibly 
contribute to endometriosis via enhanced cell 
shedding of endometrial cells by increased 
PAI-1 levels, a hypothesis which warrants fur-
ther investigations.
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